Absence of mutations in the HBsAg “a” determinant during REP 2139 therapy validates serum HBsAg reductions observed in the REP 102 protocol
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Hepatology"
DOI: 10.1016/s0168-8278(17)30822-x
Abstract: CONTACT INFORMATION Mahtab et al., 2016. Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naïve Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection. PLOS ONE 2016; 11: e156667 Martin… read more here.
Keywords: determinant rep; absence mutations; hbsag determinant; 2139 therapy ... See more keywords